HomeNewsBusinessMarketsSamvat 2074: Jhunjhunwala says mkt staring at 'very long' bull run; bets on complex generics in pharma

Samvat 2074: Jhunjhunwala says mkt staring at 'very long' bull run; bets on complex generics in pharma

Jhunjhunwala is also optimistic on the story of financial savings and feels that large part of savings being invested into equity has just started.

October 19, 2017 / 17:45 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

The big bull of D-Street, Rakesh Jhunjhunwala of Rare enterprises, believes at this juncture investors are staring at a ‘very very long bull market’. The reasons for this bullish sentiment are alive and fundamentals will only improve with every passing day, the ace investor told CNBC-TV18's Udayan Mukherjee. In such a situation, the market could take a breather sometimes.

Jhunjhunwala is optimistic on the story of financial savings and feels a large part of savings being invested into equity has just started.

Story continues below Advertisement

Insight 18 | Samvat 2074: The Story Behind Muhurat Trading

The investor is also placing a big bet on complex generics in the overall pharmaceutical space. For the sector, he said, everything that could go wrong has already gone wrong and the worst is behind. He expects pharmaceutical sector in India to grow at 15 percent every year and believes large pharma businesses in India will do well regardless of what happens in the US.

“There has been too much pessimism about the US generics market and pricing. The latter in the US market has hit a bottom. Amazon is going to sell medicines, which I think is a positive. So, Indian pharma will now have one more buyer. Just because Amazon is going to sell medicines, doesn't mean prices will crash. That is why I feel the worst with respect to the pharma space is behind us,” he told the channel, adding, in the long term, India is like the FMCG market for medicines.